PointState Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

PointState Capital’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-17,500	Closed	-$921K	–	146
2021 Q3	$921K	Buy	+17,500	New	+$1.04M	0.02%	132

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PointState Capital's LKFT Position: Q4 2021 in Review

PointState Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2021, closing a stake of 17,500 shares — an estimated $921K sold.

PointState Capital first reported a position in LKFT in Q3 2021 and held it in 1 quarter. The position peaked at $921K in Q3 2021. 83 funds tracked by Wall St. Rank hold LKFT as of Q4 2021.

PointState Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2021 after selling out during the quarter.
PointState Capital sold 17,500 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2021, an estimated $921K.
PointState Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2021 and held it in 1 quarter.
PointState Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $921K in Q3 2021.
83 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2021.

Based on PointState Capital's 13F filing for Q4 2021, filed 11 Feb 2022.